Listen to A/Prof Karin Ried on a ‘Metagenics Clinical Podcast’ – Screening for Circulating Tumour Cells (CTC)

Date: 17-06-2020

Interested in the research undertaken at NIIM?

A/Prof Karin Ried sat down with Metagenics for their ‘Metagenics Clinical Podcast’ to discuss the new NIIM ISET®-CTC test. A/Prof Karin Ried explains how the test detects CTCs, including how it can distinguish between malignant CTCs and benign circulating epithelial cells, as well as nuances around interpretation of results and the value of monitoring CTCs. Enjoy the highly informative conversation with Dr Ried.

Listen to the fascinating episode here: https://ahttps://podcasts.apple.com/fr/podcast/screening-for-circulating-tumour-cells-ctc-with-karin-ried/id1177865679?i=1000476608605pple.co/39dZ7wn

To learn more about the Screening for Circulating Tumour Cells.

*Highlights *

  1. A very good place to start – what is a CTC? (1:30)
  2. The role the ISET®-CTC test has in integrative oncology (8:00)
  3. Nuances around result interpretation (12:40)
  4. Comparing this test to marker tests (21:20)
  5. Emphasis on the role of the immune system (29:50)
  6. Delivering results to patients (33:20)
  7. Delving into cancer screening (39:00)
  8. Learnings from examining prostate cancer (40:00)
  9. The value of monitoring CTCs (53:30)
  10. Therapeutic considerations (105:00)

Useful links and resources: e.g:
– ‘New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers’, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192049/

https://niim.com.au/research-education/prostate-cancer-screening-study
https://niim.com.au/news-resources/news/2020/06/17/new-test-delivers-improved-accuracy-in-prostate-cancer-detection